Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study.

Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study. Abstract Text:

Yanzhang C Wei,Robert P Sticca,Jinhua Li,Lillia M Holmes,Kelly E Burgin,Susan Jakubchak,Hilary Bouton-Verville,Jane Williamson,Karen Meyer,Lyndon Evans,Julie Martin,Joseph J Stephenson,Steven Trocha,Sam Smith,Thomas E Wagner,

Vaccination using dendritic/tumor cell hybrids represents a novel and promising cancer immunotherapy. We have developed a technology that can instantly purify the hybrids (dendritomas) from the fusion mixture of dendritic cells (DCs) and tumor cells. Our animal studies and a phase I study of stage IV melanoma patients demonstrated that dendritoma vaccination could be conducted without major toxicity and induced tumor cell-specific immunological and clinical responses. In this pilot study, ten stage IV renal cell carcinoma patients were studied. Dendritomas were made from autologous DCs and tumor cells and administered by subcutaneous injection. After initial vaccination, three escalating doses of IL-2 (3, 6, and 9 million units each) were followed within five days. This treatment regimen was tolerated well without severe adverse events directly related to the dendritoma vaccine. Most adverse events were related to IL-2 administration or pre-existing disease. Patient-specific immune responses were evaluated by flow cytometric measurement of interferon-gamma-producing T-cells before and after vaccination in response to stimulation with tumor antigens. Nine out of nine patients eligible for the analysis showed an increase of IFN-gamma-expressing CD4+ T cells after vaccination(s); while five out of eight patients eligible for the analysis showed an increase of IFN-gamma-expressing CD8+ T cells. Clinical responses were documented in 40% of the patients, three with stabilization of disease and one with a partial response documented by a reduction in tumor size. This pilot study demonstrated that dendritoma vaccines could be administered safely to patients with metastatic renal cell carcinoma, while producing both clinical and immunologic evidence of response.

Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study. Publishing Authors By Initials

YC Wei,RP Sticca,J Li,LM Holmes,KE Burgin,S Jakubchak,H Bouton-Verville,J Williamson,K Meyer,L Evans,J Martin,JJ Stephenson,S Trocha,S Smith,TE Wagner,

For similar diagnosis: diagnostic techniques and procedures: neoplasm staging research abstracts see: diagnosis: diagnostic techniques and procedures: neoplasm staging research

PUBMED ID PMID:

MEDLINE DATE:

Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Oncology reports

VOLUME: 18

Page Numbers: 665-71

Journal Abbreviation: Oncol. Rep.

ISSN: 1021-335X

DAY: 28

MONTH: Sep

YEAR: 2007

Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9422756

Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study. Keywords Mesh Terms:

KEYWORDS: Neoplasm Staging

MESH TERMS: pathology

Chemical & Substance for Abstract: Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study. Information

Substance Name: Interleukin-2

Registry Number: 0

Grant and Affiliation Information for Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study.

AFFILIATION: Oncology Research Institute and the Cancer Treatment Center, Greenville Hospital System, Greenville, SC 29605, USA.

Country: Greece

AGENCY: United States NCI

GRANT: R21 CA101224-02

ACRONYM: CA

MEDLINETA: Oncol Rep

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study Related Publications

• A glycine N-methyltransferase knockout mouse model for humans with deficiency of this enzyme.
• A method for cultivating morphologically undifferentiated embryonic stem cells from porcine blastocysts.
• Amplitudes and directions of internal protein motions from a JAM analysis of 15N relaxation data.
• An evaluation of three policies for updating product categories in the National Retail Data Monitor.
• Antisense therapy in clinical oncology: preclinical and clinical experiences.
• Bringing geriatricians to the front lines: evaluation of a quality improvement intervention in primary care.
• Comparison of the 13C-urea blood test to histology and rapid urease testing in the diagnosis of Helicobacter pylori infection in children.
• Continued divergence in VO2max of rats artificially selected for running endurance is mediated by greater convective blood O2 delivery.
• Developmental changes in time course of recovery from inactivation in L-type calcium currents of rabbit ventricular myocytes.
• Effect of dopamine agonists or antagonists, TRH, stress and piglet removal on plasma prolactin concentrations in lactating gilts.
• En2 knockout mice display neurobehavioral and neurochemical alterations relevant to autism spectrum disorder.
• Enhanced Cd2+ -selective root-tonoplast-transport in tobaccos expressing Arabidopsis cation exchangers.
• Enzyme replacement for infantile Pompe disease: the first step toward a cure.
• Estrogen differentially modulates the cannabinoid- induced presynaptic inhibition of amino acid neurotransmission in proopiomelanocortin neurons of the arcuate nucleus.
• Identification of individual protein-ligand NOEs in the limit of intermediate exchange.
• Key design elements of a data utility for national biosurveillance: event-driven architecture, caching, and Web service model.
• Management of bipolar disorder in children and adolescents.
• Methyl balance and transmethylation fluxes in humans.
• Minimizing radiation injury and neoplastic effects during pediatric fluoroscopy: what should we know?
• NMR structural investigation of the mitochondrial outer membrane protein VDAC and its interaction with antiapoptotic Bcl-xL.
• New Constituents from Ocimum sanctum.
• Non-uniformly sampled double-TROSY hNcaNH experiments for NMR sequential assignments of large proteins.
• Plasma proteins in edematous white matter after intracerebral hemorrhage confound immunoblots: an ELISA to quantify contamination.
• Postpartum weight and body condition loss and performance of fall-calving cows.
• Steroid synthesis by the fetal part of the bovine placenta of late pregnancy in vitro: Effect of a low dose of dexamethasone in vivo.
• The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis.
• Unprotected intercourse among people living with HIV/AIDS: The importance of partnership characteristics.
• Uterine motility in the cow during the estrous cycle. II. Comparative effects of prostaglandins F(2alpha), E(2), and cloprostenol.
• Voluntary exercise and tail shock have differential effects on amphetamine-induced dopaminergic toxicity in adult BALB/c mice.
• [Effect of oral vitamin E administration on parameters of resistance to infection in swine in the early fattening stage]